Equillium to Host Analyst & Investor Day
03 Ottobre 2023 - 2:00PM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders, today announced that it will
host a virtual analyst and investor day on Monday, October 16, 2023
at 9 a.m. PT / 12:00 p.m. ET.
During the event, management will provide a brief review of
Equillium’s pipeline and a detailed review of the company’s
Multi-Cytokine Platform and clinical-stage Multi-Cytokine
Inhibitors, with a focus on its lead asset, EQ101, currently in a
Phase 2 clinical trial for moderate to severe alopecia areata.
Speaking on the topic of alopecia areata and current treatment
paradigms will be Arash Mostaghimi, MD, MPA, MPH, an assistant
professor of dermatology at Harvard Medical School, and director of
the Dermatology Inpatient Service and co-director of the complex
medical dermatology fellowship at Brigham and Women’s Hospital. As
a board-certified internist and dermatologist, Dr. Mostaghimi
specializes in the dermatologic care of patients with complex
dermatology disorders. In addition to his clinical research, he is
an advisor to several companies using novel technologies or
innovative models of care delivery.
Virtual Analyst & Investor Day Access
Analysts and investors can access the virtual event through the
webcast available on the company’s Investor Relations Events Page
or by dialing (877)-853-5247, using the meeting ID# 92612791150 and
passcode 197828. Questions from analysts and institutional
investors can be asked through either dialing or via webcast.
A replay of the presentation slides will be available on the
company's website after the event.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a tri-specific cytokine
inhibitor that selectively targets IL-2, IL-9, and IL-15; currently
under evaluation in a Phase 2 proof-of-concept clinical study of
patients with alopecia areata. EQ102: a bi-specific cytokine
inhibitor that selectively targets IL-15 and IL-21; currently under
evaluation in a Phase 1 first-in-human clinical study to include
healthy volunteers and celiac disease patients. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and a Phase 1b
clinical study of patients with lupus/lupus nephritis. Equillium
acquired rights to itolizumab through an exclusive partnership with
Biocon Limited and has entered a strategic partnership with Ono
Pharmaceutical Co., Ltd. for the development and commercialization
of itolizumab under an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; the risk that initial and
interim results of a clinical study do not necessarily predict
final results and that one or more of the clinical outcomes may
materially change as patient enrollment continues, following more
comprehensive reviews of the data, and as more patient data become
available; potential delays in the commencement, enrollment and
completion of clinical studies and the reporting of data therefrom;
changes in market conditions and alternative uses of Equillium’s
capital, including having to use cash in ways or on timing other
than expected; the sufficiency of Equillium’s capital to fund
certain clinical development efforts and whether anticipated
milestones are able to be achieved; whether Equillium is able to
grow its business and increase stockholder value over time; and
risks related to Ono’s financial condition, willingness to continue
to fund the development of itolizumab, and decision to exercise its
option, if ever, to purchase itolizumab or terminate the asset
purchase agreement. These and other risks and uncertainties are
described more fully under the caption "Risk Factors" and elsewhere
in Equillium's filings and reports, which may be accessed for free
by visiting the Securities and Exchange Commission’s website at
www.sec.gov and on Equillium’s website under the heading
“Investors.” Investors should take such risks into account and
should not rely on forward-looking statements when making
investment decisions. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Equillium undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003834264/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Mag 2023 a Mag 2024